BioWorld

June 13, 2007

Par Pharmaceutical Gains Rights To Phase III Drug From Immtech

Par Pharmaceutical Cos. Inc. gained exclusive rights in the U.S. to a Phase III drug from Immtech Pharmaceuticals Inc. for treating pneumocystis pneumonia in AIDS patients. (BioWorld Today) Read More

Coley Acquires TLR7 And TLR8 Programs From 3M For $20M

Xanthus Gets SPA Clearance For Trials In Secondary AML

NewCo News: Aquinox Targets SHIP Enzyme, Sets Sail With $14.5M Series A

Roxro Adds $42M Privately To Support Pain Drug Development

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...